[Calcium-phosphorus changes in chronic anticonvulsant therapy: effects of the administration of 25-hydroxyvitamin D3 on secondary hyperparathyroidism].
The present study represents a contribution to the knowledge of secondary hyperparathyroidism (SHP) in patients treated with anticonvulsant drugs (AC). In these subjects alterations of the calcium: phosphorus metabolism as rickets and osteomalacia are frequent; however literature data on SHP are scarce. Our research carried out on 29 adult patients under treatment with one or more AC for periods ranging from 9 months to 12 years confirmed that 25-OHD levels in the serum are low, especially in patients treated for longer times. The iPTH levels in the serum are increased with respect to normal controls, while blood calcium and phosphate levels are normal as are urine calcium and phosphate. The 25-OHD levels in serum present the same seasonal variations as the normal controls. The administration of 25-OHD3 (20 micrograms/day for 3 months) to 12 of these patients who had the lowest 25-OHD spring levels rendered the 25-OHD levels attain normal values. Cyclic AMP was normalized; serum and urine calcium and phosphorus and urinary hydroxyproline were not modified significantly. On the basis of the present data it is recommended that chronic AC treatment should be accompanied by long term administration of 25-OHD3 for prophylaxis and/or for treatment of SHP.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects*; D002112:Calcifediol / Q000097:blood / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism*; D000242:Cyclic AMP / Q000652:urine; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006962:Hyperparathyroidism, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010758:Phosphorus / Q000378:metabolism*; D012621:Seasons
D000927:Anticonvulsants; D010758:Phosphorus; D000242:Cyclic AMP; D002112:Calcifediol; D006909:Hydroxyproline; D002118:Calcium
Alterazioni calcio-fosforiche nella terapia cronica con anticonvulsivi: effetti della somministrazione di 25-OHD3 sull'iperparatiroidismo secondario.